The Future of GLP-1RAs in Obesity Treatment: Expert Perspective

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Commentary

Video

With the recent surge in demand and supply shortages, Michael Crotty, MD, discusses the future of GLP-1RA use in the treatment of obesity.

The future of glucagon-like peptide-1 (GLP-1) receptor agonists in obesity treatment holds significant promise, though current challenges such as supply shortages, cost, and insurance coverage persist. The long-term success of GLP-1 receptor agonists hinges on a multifaceted approach that incudes lifestyle interventions, medication adherence, and addressing weight bias and stigma, according to Michael Crotty, MD, a general practitioner who specializes in obesity medicine and is co-founder of My Best Weight in Dublin, Ireland. He explains in the short video above.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 8th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

June 30th 2023

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial / image credit ©JHVE photo/stock.adobe.com

December 20th 2024

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

December 17th 2024

Semaglutide 7.2 mg Achieves Weight Reduction of 21% in Late-Stage STEP UP Trial

Your daily dose of the clinical news you may have missed.

Related Content

January 17th 2025

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

The 20.7% weight loss with the high-dose of semaglutide bested the mean reduction of 17.5% seen with semaglutide 2.4 mg, according to Novo Nordisk.

August 30th 2023

FDA Proposes Sustained 5% Weight Loss to Establish Efficacy of New Antiobesity Medications

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

January 8th 2025

Obesity & Type 2 Diabetes: An Expert Discussion

In an unusual step, the agency's draft guidance recommends the efficacy benchmark for drug approval while emphasizing clinical trial structure and cohort development.

June 30th 2023

CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

December 20th 2024

Investigational Maridebart Cafraglutide Shows Promise for Obesity, T2D: Daily Dose

The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.

December 17th 2024